To provide evidence-based guidance on the optimum management of chronic pain in adult cancer survivors.
Methods
An ASCO-convened expert panel conducted a systematic literature search of studies investigating chronic pain management in cancer survivors. Outcomes of interest included symptom relief, pain intensity, quality of life, functional outcomes, adverse events, misuse or diversion, and risk assessment or mitigation.
Results
A total of 63 studies met eligibility criteria and compose the evidentiary basis for the recommendations. Studies tended to be heterogeneous in terms of quality, size, and populations. Primary outcomes also varied across the studies, and in most cases, were not directly comparable because of different outcomes, measurements, and instruments used at different time points. Because of a paucity of high-quality evidence, many recommendations are based on expert consensus.
INTRODUCTION
As a result of extraordinary advancements in diagnosis and treatment, approximately 14 million individuals with a history of cancer (excluding nonmelanomatous skin cancers) are living in the United States. 1 Two thirds of these individuals are surviving $ 5 years after diagnosis.
2 Unfortunately, these impressive outcomes in survival often come with physical, psychosocial, and financial burdens as a result of the tumor, exposure to cancer treatment, or other medical comorbidities. Chronic pain can be a serious, negative consequence of surviving cancer. Although estimates vary, the prevalence of pain in cancer survivors has been reported to be as high as 40%. [3] [4] [5] Predictors include the type and invasiveness of the tumor, the treatment regimen used, the time since cancer treatment, and the efficacy of initial pain therapy. Significant pain is associated with impaired quality of life in this population. 6 Many guidelines and recommendations have been advanced to support the management of cancer pain, yet the focus of these documents has been primarily on relieving acute pain or pain associated with advanced disease. 7, 8 Few evidence-based cancer pain guidelines address the more nuanced care required when pain persists for months or years. This situation is in part caused by the relative absence of studies exploring the experiences of chronic pain in cancer survivors, or the long-term safety and effectiveness of analgesic interventions.
Whereas opioid-based pharmacotherapy is widely accepted as the foundation of care for acute pain or pain associated with advanced cancer, the management of patients who are free of
THE BOTTOM LINE (CONTINUED)
Recommendation 2.11. Clinicians should assess risks of adverse effects of opioids used for pain management. Table 7 lists opioid-related long-term adverse effects. (Evidence-based and informal consensus; benefits outweigh harms; evidence quality: intermediate strength of recommendation: moderate) Qualifying statement. Although there is literature describing dysimmune effects and tumor proliferative effects from opioid drugs (both of which may be of particular concern in the cancer survivor population), there is insufficient evidence to determine whether there are clinically important risks. The expert panel believes that further clinical investigation is required to assess these concerns. In the absence of actionable data, physicians should be made aware of these evolving questions, and patients and their families may be informed about them as part of a discussion of the potential harms of long-term opioid therapy, as described in Table 7 .
RISK ASSESSMENT, MITIGATION, AND UNIVERSAL PRECAUTIONS WITH OPIOID USE
Recommendation 3.1. Clinicians should assess the potential risks and benefits when initiating treatment that will incorporate long-term use of opioids. (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: moderate) Recommendation 3.2. Clinicians should clearly understand terminology such as tolerance, dependence, abuse, and addiction as it relates to the use of opioids for pain control. (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: moderate) Recommendation 3.3. Clinicians should incorporate a universal precautions approach to minimize abuse, addiction, and adverse consequences of opioid use such as opioid-related deaths. Clinicians should be cautious in coprescribing other centrally acting drugs, particularly benzodiazepines (Table 7) . (Evidence-based and informal consensus; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate) Recommendation 3.4. Clinicians should understand pertinent laws and regulations regarding the prescribing of controlled substances. (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: moderate) Recommendation 3.5. Clinicians should educate patients and family members regarding the risks and benefits of long-term opioid therapy and the safe storage, use, and disposal of controlled substances. Clinicians are encouraged to address possible myths and misconceptions about medication use and should educate patients about the need to be cautious when using alcohol or sedating over-the-counter medications or in receiving centrally acting medications from other physicians. (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: moderate) Qualifying statement. Education and information about treatment should ideally take into account the patient's literacy level and the need for interpreters and should be provided in a culturally congruent manner. Recommendation 3.6. If opioids are no longer warranted, clinicians should taper the dose to avoid abstinence syndrome. The rate of tapering and the use of cotherapies to reduce adverse effects should be individualized for each patient. (Evidencebased and informal consensus; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate)
Additional Resources: More information, including a Data Supplement with additional evidence tables, a Methodology Supplement with information about evidence quality and strength of recommendations, slide sets, and clinical tools and resources, is available at www.asco.org/chronic-pain-guideline and www.asco.org/guidelineswiki. Patient information is available at www.cancer.net ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate cancer after treatment, or who are living with cancer as a chronic illness, is not grounded in broad consensus. The management of these populations with chronic cancer pain requires greater consideration of a multimodality plan of care that balances pharmacologic and nonpharmacologic techniques and may necessitate the involvement of an interdisciplinary team; the goals of treatment in these populations may focus on improving function and limiting the long-term adverse effects of pain and of its treatment, as much or more as they do on improving comfort. 9, 10 As the population of cancer survivors expands, all clinicians, including oncologists, advanced practice providers, and primary care physicians who interact with these individuals, will require the knowledge and skills to implement best practices in the management of chronic pain. When analgesic drugs are used, the imperative to prescribe safely must expand beyond immediate adverse effects, such as the resulting respiratory depression or constipation associated with opioids, to incorporate awareness and mitigation of the long-term consequences of these and other analgesic agents. The purposes of this systematic review and evidence-based guideline are to evaluate randomized controlled trials (RCTs) and other fundamental studies regarding chronic pain in cancer survivors reported in the literature, to compare outcomes among trials, and to provide guidance to clinicians on the effectiveness of treatment options for pain in adults with a history of cancer.
Guideline Question
This clinical practice guideline addresses how chronic pain in survivors of adult cancers should be managed.
METHODS

Guideline Development Process
The expert panel met in person and via teleconference and corresponded through e-mail. On the basis of the consideration of the evidence, the authors were asked to contribute to the development of the guideline, to provide critical review, and to finalize the guideline recommendations. Members of the expert panel were responsible for reviewing and approving the penultimate version of the guideline, which was then circulated for external review and submitted to Journal of Clinical Oncology for editorial review and consideration for publication. All ASCO guidelines are ultimately reviewed and approved by the expert panel and the ASCO Clinical Practice Guideline Committee prior to publication (Appendix Table A1 , online only).
The recommendations were developed by an expert panel with multidisciplinary representation, who used a systematic review (1996 to 2015) of RCTs, observational studies, and clinical experience. In some selected cases in which evidence was lacking, but where there was a high level of agreement among the members of the panel and where the benefits clearly outweighed the harms, informal consensus was used (as noted in Recommendations).
Articles were selected for inclusion in the systematic review of the evidence if they:
• Included adult cancer survivors at risk of or with chronic pain, although literature on chronic pain in other adult populations was also considered because of the paucity of evidence in cancer survivors
• Considered either cancer pain or noncancer pain • Investigated the efficacy or harms of pharmacologic or nonpharmacologic interventions for pain management
• Reported results on any of the following outcomes: symptom relief; patient-reported pain intensity (pain rating scale); participant-reported global impression of clinical change; quality of life (measured by a validated, reliable instrument (eg, the Functional Assessment of Cancer Therapy-Endocrine Symptoms and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire); disability measure; pain interference; functional outcomes; caregiver end points such as distress or decision burden; adverse events, including misuse or diversion; barriers; or risk assessment or mitigation
• Were fully published, English-language reports of systematic reviews, meta-analyses, RCTs, or comparative observational studies Articles that considered acute pain were not included. Studies were also excluded from the systematic review if they were meeting abstracts that were not published subsequently in peer-reviewed journals, or were editorials, commentaries, letters, news articles, case reports, or narrative reviews. The guideline recommendations are crafted, in part, using the GuideLines Into Decision Support methodology.
11 In addition, a guideline implementability review was conducted. On the basis of the implementability review, revisions were made to the draft to clarify recommended actions for clinical practice. Ratings for the type and strength of recommendation, evidence, and potential bias are provided with each recommendation (see Methodology Supplement for more detail).
Detailed information about the methods used to develop this guideline, including an overview (eg, panel composition, development process, and revision dates); literature search and data extraction; the recommendation development process; and quality assessment, is available in the Methodology Supplement and Data Supplement at www.asco.org/ chronic-pain-guideline.
The ASCO panel and guidelines staff will work with co-chairs to keep abreast of any substantive updates to the guideline. On the basis of formal review of the emerging literature, ASCO will determine the need to update. The Methodology Supplement (available at www.asco.org/chronic-painguideline) provides additional information. This is the most recent information as of the publication date. For updates and the most recent information or to submit new evidence, please visit www.asco.org/chronic-pain-guideline and the ASCO Guidelines Wiki (www.asco.org/guidelineswiki).
Guideline Disclaimer
The clinical practice guidelines and other guidance published herein are provided by ASCO to assist providers in clinical decision making. The information herein should not be relied on as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Furthermore, the information is not intended to substitute for the independent professional judgment of the treating provider, because the information does not account for individual variation among patients. Recommendations reflect high, moderate, or low confidence that the recommendation reflects the net effect of a given course of action. The use of such words as "must," "must not," "should," and "should not" indicates that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ASCO provides this information on an as is basis and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information, or for any errors or omissions.
Guideline and Conflicts of Interest
The expert panel was assembled in accordance with ASCO's Conflict of Interest Management Procedures for Clinical Practice Guidelines (Procedures, summarized at http://www.asco.org/rwc). Members of the panel completed ASCO's disclosure form, which requires disclosure of financial and other interests that are relevant to the subject matter of the guideline, including relationships with commercial entities that are reasonably likely to experience a direct regulatory or commercial impact as a result of promulgation of the guideline. Categories for disclosure include employment; leadership; stock or other ownership; honoraria; consulting or advisory role; speakers' bureau; research funding; patents, royalties, other intellectual property; expert testimony; travel, accommodations, expenses; and other relationships. In accordance with the procedures, the majority of the members of the Panel did not disclose any such relationships.
RESULTS
Characteristics of Studies Identified in the Literature Search
A total of 35 systematic reviews, nine RCTs, and 19 comparative studies met the eligibility criteria and form the evidentiary basis for the guideline recommendations. Two existing clinical practice guidelines were also identified to help inform the discontinuation of long-term opioid therapy. The included studies are heterogeneous with respect to patient populations, sample size, methodologic quality, treatment duration, and outcome measures. The primary outcomes varied across studies and, in the majority of cases, were not directly comparable because of different outcomes, measurements, and instruments used at different time points. This diversity precluded a quantitative analysis, and, as such, only a qualitative review was performed. Table 1 outlines the studies that were particularly pertinent to the development of the recommendations.
Study Quality Assessment
An assessment of study quality was performed for all the included evidence by one methodologist. Systematic reviews and meta-analyses were assessed for quality using A Measurement Tool to Assess Systematic Reviews (AMSTAR). 12 Design elements such as blinding, allocation concealment, placebo control, intention to treat, funding sources, and so forth, were assessed for RCTs. Methodologic criteria assessed for other study designs included type of data collection, sampling method, and conflicts of interest. In general, most of the identified studies exhibited a low to intermediate potential risk of bias. AMSTAR scores ranged from 3 to 11 out of a possible 11 points. Overall, the included systematic reviews were conducted in a rigorous fashion; however, many of the primary studies included in these reviews, and other primary RCTs identified for inclusion in this analysis, suffered from industry sponsorship, short follow-up, lack of blinding, and lack of reporting of intention-to-treat analyses. Moreover, outcomes varied greatly across studies and were often assessed by different methods or measurement scales. Refer to the Data Supplement for ratings of overall potential risk of bias.
Key Outcomes of Interest
Data on key outcomes of interest are summarized in Table 2 and are reported in detail in Tables 8 to 14 in the Data Supplement. Because all outcomes are described in detail in the Data Supplement, only studies that detected a significant difference for any of the outcomes of interest are discussed here.
Pain Measures
Measures of pain intensity and relief were considered in the vast majority of studies. Pain outcomes were measured in many ways, including pain ratings on a visual analog scale (VAS) and proportion of patients achieving a 30% or a 50% reduction in pain. Statistically significant results were seen for both nonpharmacologic and pharmacologic interventions.
In one meta-analysis 36 and three RCTs, 38-40 exercise and physical therapy had a small but significant impact on pain. Three systematic reviews, [42] [43] [44] two with meta-analyses, 43, 44 confirmed that acupuncture and massage were effective in improving pain. Furthermore, psychological-based interventions showed promise, with moderate and significant effects on pain reported in six systematic reviews that considered acceptance-based interventions, patient education, relaxation, guided imagery, meditation, hypnosis, and music interventions. 45, [52] [53] [54] [55] Finally, interventional therapies had demonstrable effects on pain improvement. Evidence exists for celiac plexus block (CPB), 46 implantable intrathecal drug delivery systems (IDDs), 51 percutaneous vertebroplasty, and kyphoplasty. 49 The effectiveness of adjuvant analgesics in pain outcomes was also evident. Six systematic reviews on antidepressants 13,23 and anticonvulsants 13,20-22 showed significant and clinically relevant effects on pain. Statistical and clinically meaningful improvements in pain were reported in four systematic reviews of opioid therapy. [13] [14] [15] 18 Similarly, cannabinoids were reported to provide statistically significant analgesic effect in four systematic reviews, 29-32 one RCT, 34 and one observational study. 
Nonpharmacologic treatment Physical medicine and rehabilitation
Two systematic reviews, three RCTs Table 8 Integrative and neurostimulatory therapies
Six systematic reviews Table 9 Interventional therapies One systematic review, three RCTs, two observational studies Table 10 Psychological approaches Seven systematic reviews Table 11  Pharmacologic treatment Adjuvant analgesics 10 systematic reviews, one RCT Table 12  Cannabinoids Five systematic reviews, one RCT, one observational study Table 13 Opioids Six systematic reviews, one RCT 
Physical medicine and rehabilitation
www.jco.org 
Boldface denotes statistically significant differences between treatment groups; ↑, difference in outcomes favoring the intervention arm; ↓, difference in outcomes not favoring the intervention arm;
↑-, differences favoring the intervention in some studies in a systematic review and not favoring in others;
-, no meaningful differences reported between groups or data were not reported.
Abbreviations: CBT, cognitive-behavioral therapy; CPB, celiac plexus block; IDD, intrathecal drug delivery system; NSAID, nonsteroidal anti-inflammatory drug; PT, physical therapy; QOL, quality of life; RCT, randomized clinical trial; TENS, transcutaneous electrical nerve stimulation; TPVB, thoracic paravertebral block.
Quality of Life
A systematic review of mindfulness-based stress reduction (MBSR) 56 found MBSR to be effective in improving and sustaining quality of life in breast cancer survivors. Thoracic paravertebral block (TPVB) was also reported to result in better physical and mental health-related quality of life in randomly assigned patients. 47 
Level of Function
Improvement in function was reported in four studies. Physical activity was one intervention shown to improve physical function, as measured by the 36-Item Short Form Health Survey in an RCT, although the effect was modest. 37 Implanted drug delivery systems, kyphoplasty, and vertebroplasty significantly improved physical function and disability for patients with chronic pain. 48, 50 One systematic review reported that, of five trials considering level of function, two found a statistically significant improvement in function as assess by the Pain Disability Index and Fibromyalgia Impact Questionnaire in patients who used cannabis-based medicines compared with placebo.
32
Opioid or Analgesic Consumption A number of adjuvant analgesic studies considered opioid consumption as an outcome, but most failed to show a statistically significant difference. However, in one systematic review, the addition of nonsteroidal anti-inflammatory drugs (NSAIDS) to opioids was reported to result in a reduction of opioid consumption.
27
In an observational study, interventional procedures such as percutaneous vertebro-and kyphoplasty led to a reduction in analgesic consumption.
49
RECOMMENDATIONS
Clinical Question
How should chronic pain be managed in the adult cancer survivor?
1. SCREENING AND COMPREHENSIVE ASSESSMENT Recommendation 1.1. Clinicians should screen for pain at each encounter. Screening should be performed and documented using a quantitative or semiquantitative tool. (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: strong)
Qualifying statement. Screening may be as simple as a twoquestion verbal screen (eg, "Have you had frequent or persistent pain since the last time you were seen?" and if the answer is yes, "How severe has this pain been, on average, during the past week?") A simple screen of this type, which quantitates the response to the second question using a verbal rating scale or a numeric scale, can identify patients who should undergo an initial comprehensive pain assessment designed to determine cause and to develop a treatment plan. Recommendation 1.2. Clinicians should conduct an initial comprehensive pain assessment. This assessment should include an in-depth interview that explores the multidimensional nature of the pain (pain descriptors, associated distress, functional impact, and related physical, psychological, social, and spiritual factors) and captures information about cancer treatment history and comorbid conditions, psychosocial and psychiatric history (including substance use), and prior treatments for the pain. The assessment should characterize the pain, clarify its cause, and make inferences about pathophysiology. A physical examination should accompany the history, and diagnostic testing should be performed when warranted. (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: moderate) Recommendation 1.3. Clinicians should be aware of chronic pain syndromes resulting from cancer treatments, the prevalence of these pain syndromes, risk factors for individual patients, and appropriate treatment options. A list of common cancer pain syndromes can be found in Table 3 . (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: moderate) Recommendation 1.4. Clinicians should evaluate and monitor for recurrent disease, second malignancy, or late-onset treatment effects in any patient who reports new-onset pain. (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: moderate) Literature review, analysis, and clinical interpretation. These recommendations were developed through informal consensus of the expert panel. Although there are few trials investigating optimal evaluation of pain in cancer survivors, screening and multidimensional assessment of pain provide data to inform clinical practice. Awareness of the array of potential pain syndromes will guide the treatment plan. Because of the risk of recurrence or secondary malignancy, these must also be considered when conducting this evaluation. Clinicians should also be aware that many patients with a history of cancer may also report chronic pain unrelated to the cancer, such as arthritis, degenerative disk disease, or diabetic neuropathy
TREATMENT AND CARE OPTIONS
Recommendation 2.1. Clinicians should aim to enhance comfort, improve function, limit adverse events, and ensure safety in the management of pain in cancer survivors. (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: moderate) Recommendation 2.2. Clinicians should engage patient and family/caregivers in all aspects of pain assessment and management. (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: moderate) Recommendation 2.3. Clinicians should determine the need for other health professionals to provide comprehensive pain management care in patients with complex needs. If deemed necessary, the clinician should define who is responsible for each aspect of care and refer patients accordingly. (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: moderate)
Nonpharmacologic Interventions
Recommendation 2.4. Clinicians may prescribe directly or refer patients to other professionals to provide the interventions outlined in Table 4 to mitigate chronic pain or improve painrelated outcomes in cancer survivors. These interventions must take into consideration pre-existing diagnoses and comorbidities and should include an assessment for adverse events. (Evidencebased; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate)
Literature review, analysis, and clinical interpretation. A number of randomized trials investigated the use of nonpharmacologic therapies in the management of chronic pain. The evidence to support their use is modest at best. Many of the studies had small sample sizes, were of short durations, and had methodologic limitations that increased their risk of bias. However, there was some consistency in the findings and most often those therapies had minimal adverse effects. In areas where the evidence was weak or unavailable, informal consensus of the expert panel was used to develop the recommendations on nonpharmacologic interventions. There were no compelling data to recommend one of these therapies over another. In fact, a variety of these interventions may be selected on the basis of patient/family goals, potential toxicities, ability to participate, and cost.
Physical medicine and rehabilitation.
• A Cochrane review 36 of seven RCTs evaluated the effectiveness of exercise on pain in adult cancer survivors who had completed active treatment. Modes of exercise included strength training, resistance training, walking, cycling, yoga, qigong, or tai chi. As measured on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-30, a significant reduction in pain was reported at 12 weeks (standardized mean difference [SMD], 20.29; 95% CI, 20.55 to 20.04) in patients in the exercise intervention groups compared with those randomly assigned to usual care or other nonexercise interventions. However, no difference was seen in longer follow-up periods.
• A statistically significant improvement in physical function (pooled difference 3.0 [95% CI, 0.7 to 5.3), P 5 .01), as measured by the 36-Item Short Form Health Survey, was reported in cancer survivors who were randomly assigned to physical activity that included aerobic, resistance, or weight training in 34 RCTs included in a systematic review with meta-analysis. 37 Because the minimal clinically important reported that a multidimensional physical therapy program including aerobic and strengthening exercises also decreased neck pain (effect size, 2.72) and shoulder pain (effect size, 2.45) in 44 breast cancer survivors. The addition of onceper-week cognitive-behavioral therapy to a 12-week physical training program did not enhance the already beneficial effect of physical training on the quality of life of cancer survivors over a 1-year period.
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Integrative therapies.
• A recent Cochrane review 41 examining the effectiveness of acupuncture in reducing cancer-related pain in five RCTs concluded that there was insufficient evidence to judge its effectiveness. In another systematic review of 11 RCTs, effect size estimates for significant pain studies ranged from 1.11 to 2.10 for true acupuncture and from 20.45 to 0.45 for sham. 42 A third meta-analysis 43 of 437 patients with cancer reported that acupuncture plus drug therapy significantly improved pain (risk ratio, 1.36; 95% CI, 1.13 to 1.64; P 5 .003) compared with drug therapy alone.
• Meta-analytic results of massage therapy compared with no massage or conventional care in patients with cancer 44 revealed a significant reduction in pain with massage (SMD, 21.25; 95% CI, 21.63 to 20.87; P , .001) when data from nine RCTs and three nonrandomized controlled clinical trials were pooled. In a subgroup analysis that was based on different time periods of measurement, massage had a significant effect in reducing cancer pain (SMD, 20.70; 95% CI, 20.99 to 20.41; P , .001) in two studies.
• Four studies evaluating the effectiveness of music interventions on pain were reported in a systematic review. 45 Significant preto post-treatment reductions in pain were observed in two studies of hospitalized patients with cancer pain, but no difference in pain was found the other two studies.
Interventional therapies.
• A Cochrane review 46 of CPB trials in patients with pancreatic cancer found improved pain, as measured on a VAS, at 4 weeks in patients receiving CPB over those in the control groups. Moreover, opioid consumption was significantly lower in patients receiving CPB, and its safety profile makes this a viable option in indicated patients.
• Although TPVB did not reduce the incidence of chronic pain at 3 and 6 months in 180 women undergoing radical mastectomy, patients randomly assigned to TPVB did report less severe chronic pain, exhibited fewer signs and symptoms of chronic pain, and experienced better physical and mental health-related quality of life compared with patients randomly assigned to general anesthesia only.
47
• A prospective study reported improvements in pain and function from baseline to 36 months in participants with chronic nonmalignant pain who were implanted with a drug delivery system. In contrast, participants who were not treated via an intrathecal device showed a considerable decline in physical function.
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• In an RCT of patients with cancer and painful vertebral compression fractures, kyphoplasty was reported to be an effective and safe treatment that improved scores on the Roland-Morris disability questionnaire. 48 Both percutaneous vertebro-and kyphoplasty performed for vertebral body fractures in a consecutive group of patients with cancer also provided a significant reduction in VAS pain scores, which were sustained for up to 1 year. 49 Moreover, analgesic consumption was reduced at 1 month.
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• One of the first trials 51 investigating implantable IDDSs found that 84.5% of patients with IDDS achieved clinical success compared with 70.8% of patients receiving comprehensive medical management (CMM) (P 5 .05). Patients with IDDS also achieved a $ 20% reduction in both pain VAS and toxicity (57.7% v 37.5%, P 5.02). The mean CMM VAS score showed a 39% reduction compared with a 52% reduction for the IDDS group (P 5 .055). Moreover, mean toxicity scores fell by 17% for the CMM group versus 50% for the IDDS group (P 5 .004).
Psychological approaches.
• A systematic review and meta-analysis of acceptance-based interventions for the treatment of chronic pain 54 reported that, in 10 studies, a moderate and significant effect on pain (pooled SMD, 0.37), physical well-being (pooled SMD, 0.35), and quality of life (pooled SMD, 0.41) was revealed.
• Two systematic reviews with meta-analyses evaluating the effectiveness of psychosocial interventions including patient education, relaxation, guided imagery, meditation or hypnosis, and supportive group therapy on pain in patients with cancer and cancer survivors 52,53 found a statistically significant overall effect for the interventions.
• A systematic review investigating the effectiveness of hypnosis on pain in 1,357 women with breast cancer reported that hypnosis had a positive influence on pain and distress in seven trials.
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• Four studies evaluating the effectiveness of relaxation interventions on pain were reported in a systematic review. 45 Significantly greater pain relief was seen in three of these trials that included hospitalized patients with cancer pain, outpatients with chronic cancer pain, and women with earlystage breast cancer.
• A systematic review considering MBSR found that MBSR was effective in improving quality of life in breast cancer survivors. 56 These effects were maintained at 6-and 12-month follow-ups.
Neurostimulatory therapies.
• A Cochrane review 57 of three RCTs investigating the effectiveness of transcutaneous electrical nerve stimulation (TENS)
www.jco.org in a total of 88 patients with cancer-related pain found that the studies differed in methodologic quality, mode of TENS used, treatment duration, and outcomes measured. Only one study, designed as a feasibility study and not measuring true effect, suggested that TENS may improve bone pain in patients with cancer. The other two studies did not find significant differences between TENS and a control group, although one of these studies was underpowered. Few adverse effects were reported. The authors concluded that there was insufficient evidence to indicate whether TENS should be used in pain management.
Pharmacologic Interventions Miscellaneous Analgesics
Recommendation 2.5. Clinicians may prescribe the following systemic nonopioid analgesics and adjuvant analgesics to relieve chronic pain and/or improve function in cancer survivors in whom no contraindications, including serious drug-drug interactions exist:
• 58 although it is illegal on the federal level. Currently, there is insufficient evidence to recommend medical cannabis for first-line management of chronic pain in cancer survivors. However, evidence suggests it is worthy of consideration as an adjuvant analgesic or in the management of refractory pain conditions. There is also insufficient evidence to recommend one particular preparation of cannabis over another, and the Food and Drug Administration has not approved any drug product containing or derived from botanical marijuana.
Literature review, analysis, and clinical interpretation.
• A systematic review considering the addition of NSAIDS to opioids found improved analgesia and a reduction of opioid consumption in patients with cancer pain.
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• Nabal et al 27 considered the addition of paracetamol to step 3 opioid treatment and found only marginal effectiveness reported in one of five trials included in their review.
• Two systematic reviews found that antidepressants such as venlafaxine can be effective for at least moderate pain relief in patients with neuropathic pain conditions.
13,23
• Anticonvulsants were reported to have a clinically relevant effect on neuropathic pain conditions in four systematic reviews. 13, [20] [21] [22] The best evidence supports gabapentin and pregabalin.
• Current evidence on the effectiveness of ketamine is insufficient to make a recommendation for routine clinical use. Two systematic reviews 24,25 considering ketamine as an adjuvant to opioids reported that ketamine can reduce opioid requirement in patients with chronic pain that is refractory to opioids. However, its effectiveness in pain control remains unclear. Increased adverse events are also a concern.
• A Cochrane review 28 that included six studies and 2,073 patients found evidence that high-concentration (8%) topical capsaicin worked in only two types of neuropathic pain: pain after shingles and nerve-injury pain resulting from HIV infection. Evidence of effectiveness in other types of neuropathy is limited. Localized skin reactions are common.
• The analgesic effect of corticosteroids in cancer pain was assessed in a systematic review of four studies. Effectiveness results were inconsistent; however, toxicity associated with corticosteroids, particularly over 8 weeks, was a serious concern. 64, 65 and tumor proliferative effects 1,66-69 from opioid drugs (both of which may be of particular concern in the cancer survivor population), there is insufficient evidence to determine whether there are clinically important risks. The expert panel believes that further clinical investigation is required to assess these concerns. In the absence of actionable data, physicians should be made aware of these evolving questions, and patients and their families may be informed about them as part of a discussion of the potential harms of long-term opioid therapy, as described in Table 7 .
• Six systematic reviews 13-18 evaluated the effectiveness of opioids in patients who suffered from either cancer or non-cancer-related chronic pain. Each systematic review received a high quality rating, although the quality of the primary studies included in these reviews did vary considerably. Of particular note, the follow-up periods in the primary studies ranged from , 7 days only to 24 months. Long-term effectiveness was considered in the 2012 American Society of Interventional Pain Physicians' Guideline for Responsible Opioid Prescribing in Chronic Non-Cancer Pain, 70 but the lower-quality evidence available for long-term treatment periods precluded clear results. Studies used to inform the recommendations are discussed below and in Table 13 in the Data Supplement.
• The proportion of patients who reported a clinically meaningful improvement in neuropathic cancer pain while receiving opioids was 0.95 (95% CI, 0.93 to 0.96) in a systematic review of four studies. 13 Mean pain reduction was reported to be 82%, whereas mean absolute risk of harm in patients receiving active treatment was 0.06 (95% CI, 0.02 to 0.18).
• Considering pain relief as the primary outcome, a systematic review of nine RCTs 14 reported that, although transdermal fentanyl was superior to oral codeine/acetaminophen, it had efficacy equal to that of other opioids. Similarly, morphine, methadone, and oxycodone all had comparable efficacy.
• A systematic review 15 of adults suffering from chronic pain reported that in three trials, tapentadol showed a 30% improvement in pain relief (relative effectiveness, 0.68) and a 50% improvement in pain relief (relative effectiveness, 0.75) compared with oxycodone in patients with severe chronic pain. Similar results were seen in patients with moderate chronic pain on the basis of four trials. Tapentadol did have significantly more treatment discontinuation because of adverse effects than did placebo (OR, 0.33; 95% CI, 0.27 to 0.40) but it had fewer discontinuations than did morphine (OR, 2.03), oxycodone (OR, 2.31), transdermal fentanyl (OR, 1.82), oxymorphone, (OR, 4.27) and hydromorphone (OR, 2.38). The beneficial effects of tapentadol reported in this review may be attributed in part to the improved tolerability and fewer drop-outs in tapentadoltreated patients. 20 Moreover, the vast majority of the included trials in this systematic review had questionable potential sources of bias, and the systematic review itself was industry sponsored.
• In adult patients with moderate to severe chronic cancer pain never treated with strong opioids, hydromorphone showed no evidence of superior effectiveness over morphine or oxycodone in a systematic review of nine RCTs, 16 yet adverse effects such as diarrhea and sedation were more common.
• The systematic review by King et al, 17 including 14 RCTs and one meta-analysis, found that mean pain scores were no different in patients with moderate to severe cancer-related pain who received oxycodone and those who received morphine and hydromorphone (pooled standardized mean difference, 0.04; P 5.8). Considering the opioids separately, pain scores were reported to be higher for oxycodone compared with morphine and lower for oxycodone compared with hydromorphone. However, the authors questioned the clinical significance of these differences.
17
• A meta-analysis 18 of five RCTs found that the pooled mean difference in pain intensity as measured on a VAS for 40 to 100 mg of oxymorphone was 213 (95% CI, 217 to 29) compared with placebo (P , .001). Opioid-related adverse effects included nausea, vomiting, dizziness, headache, constipation, sedation, somnolence, and itching.
• Although opioids are the foundation of cancer pain management in moderate to severe acute pain as well as in pain caused by advanced disease, the efficacy of long-term use in survivors has not been well established. The balance between potential risks and benefits must be weighed when considering the long-term use of these agents in people who are surviving cancer. Benefits are no longer simply evaluated on the basis of pain relief but must also include improvements in function, tailored to the abilities of the individual.
RISK ASSESSMENT AND MITIGATION AND UNIVERSAL PRECAUTIONS WITH OPIOID USE
Recommendation 3.1. Clinicians should assess the potential risks and benefits when initiating treatment that will incorporate long-term use of opioids. (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: moderate) Recommendation 3.2. Clinicians should clearly understand terminology such as tolerance, dependence, abuse, and addiction as it relates to the use of opioids for pain control. (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: moderate) Recommendation 3.3. Clinicians should incorporate a universal precautions approach to minimize abuse, addiction, and adverse consequences of opioid use such as opioid-related deaths. Clinicians should be cautious in coprescribing other centrally acting drugs, particularly benzodiazepines (Table 7) . (Evidencebased and informal consensus; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate) 
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Recommendation 3.4. Clinicians should understand pertinent laws and regulations regarding the prescribing of controlled substances. (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: moderate) Recommendation 3.5. Clinicians should educate patients and family members regarding the risks and benefits of long-term opioid therapy and the safe storage, use, and disposal of controlled substances. Clinicians are encouraged to address possible myths and misconceptions about medication use and should educate patients about the need to be cautious when using alcohol or sedating over-the-counter medications, or in receiving centrally acting medications from other physicians. (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: moderate)
Qualifying statement. Education and information about treatment should ideally take into account the patient's literacy level and the need for interpreters and should be provided in a culturally congruent manner.
Recommendation 3.6. If opioids are no longer warranted, clinicians should taper the dose to avoid abstinence syndrome. The rate of tapering and the use of cotherapies to reduce adverse effects should be individualized for each patient. (Evidence-based and informal consensus; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate)
Literature review, analysis, and clinical interpretation. Chronic pain management using the universal precaution approach to assess and manage patients happens in a multistep process. 71 The rationale for adopting a universal precautions approach is a reduction in stigma, an improvement in patient care, and a containment of overall risk. 72 Evidence supporting various aspects of these steps is presented below. Where evidence is sparse, weak, or absent, recommendations were developed through consensus.
• A number of validated risk-assessment instruments and screening questionnaires are available to help identify patients prone to misuse or those currently misusing prescribed opioids. 77 These tools vary in how they are conducted, but all offer clinicians resources for conducting risk stratification.
• Boscarino and colleagues 78 found that dependence was associated with age , 65 years (OR, 2.33; P 5 .001), opioid abuse history (OR,3.81; P , .001), high dependence severity (OR, 1.85; P 5 .001), major depression (OR, 1.29; P 5 .022), and psychotropic medication use (OR, 1.73; P 5.006). A combination of four variables (age, depression, psychotropic medications, and pain impairment) predicted increased risk of current dependence (OR, 8.01; P , .001). Furthermore, patient history of severe dependence and opioid abuse increased this risk substantially (OR, 56.36; P , .001). Similar results were reported in a cross-sectional study of 597 primary care patients with chronic pain.
79 Prescription drug use disorder was found to be concentrated among those with a family history of substance use disorders, those who had spent time in jail, current cigarette smokers, male sex, white ethnicity, those with pain-related functional limitations, and those with post-traumatic stress disorder (PTSD). White et al 80 used data from medical and prescription drug claims to develop models that identify patients at risk of prescription opioid abuse or misuse. As in other studies, factors associated with a risk of prescription opioid abuse or misuse included age 18 to 24 years, male sex, $ 12 opioid prescriptions, opioid prescriptions from three or more pharmacies, early prescription opioid refills, escalating morphine dosages, psychiatric outpatient visits, hospital visits, diagnoses of nonopioid substance abuse, depression, PTSD, and hepatitis.
• Prospective studies have shown that adherence monitoring with a controlled substance agreement, periodic monitoring, periodic drug testing, pill counts, and education when necessary served to reduce controlled substance abuse and increase compliance.
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A systematic review investigating the effectiveness of opioid treatment agreements and urine drug testing in reducing opioid misuse among patients with chronic noncancer pain found a decrease in opioid misuse with the use of treatment agreements as part of the opioid management strategy. 87 Absolute risk reductions ranged from 6.5% (95%, CI 1.3% to 11.7%) to 22.9% (95% CI, 17.3% to 28.7%) in four controlled studies.
• Existing guidelines 88, 89 and systematic reviews 90 offer recommendations for practitioners aiming to discontinue longterm opioid therapy.
• Most of the studies evaluating risk factors associated with misuse have been conducted in people diagnosed with noncancer pain syndromes. There is no evidence to suggest that people surviving cancer, who might also have PTSD-like symptoms, would be at reduced risk. In fact, some populations may be at more risk of misuse in concert with lifestyle choices that may have contributed to the development of cancer (eg, smoking, excess alcohol intake, obesity). Tools such as agreements, urine drug testing, and use of drug monitoring programs that may mitigate risk are available, although more information is needed to determine which are most effective in the setting of cancer survivorship.
DISCUSSION
Chronic pain can be a serious negative consequence of surviving cancer, yet the magnitude of the problem is poorly understood. One challenge faced by the committee is the divergence in the definitions of survivors. Although the committee upholds the definition advanced by the National Coalition for Cancer Survivorship, which considers anyone to be a survivor from the moment of diagnosis through the rest of their life, this would have diluted the primary aim of this guideline, which is to explore pain as a later phenomenon of cancer and its treatment. Therefore, we used the National Cancer Institute's Office of Cancer Survivorship characterization of a survivor as a person with a history of cancer who is beyond the acute diagnosis and treatment phase. The number of these survivors is greatly increasing, nearing 14 million in the United States. Two thirds of these individuals are surviving $ 5 years after diagnosis, supporting the need to study pain in this growing population. 2 Estimates of the prevalence of pain in cancer survivors vary widely and have been reported to be as high as 40%. [3] [4] [5] Much of the variability in prevalence is a result of the heterogeneity of the populations studied. Risk factors for chronic pain in survivors include the type and invasiveness of the tumor, the treatment regimen used, the time since cancer treatment, and the efficacy of initial pain therapy. Because significant pain is associated with impaired quality of life in this population, 6 there is an urgent need to better characterize pain syndromes specific to the survivor. This information will allow greater understanding of underlying mechanisms, potential therapies, and optimally, preventive measures. However, even with a fairly well-characterized pain syndrome that seems to be more homogenous in origin and presentation, guideline development for painful cancer conditions can be challenging. The ASCO guideline, Prevention and Management of ChemotherapyInduced Peripheral Neuropathy (CIPN) in Survivors of Adult Cancers, 91 found few high-quality, consistent trials and was unable to make a recommendation regarding any agent for prevention of CIPN. In addition, duloxetine was the only agent recommended by the guideline panel for the treatment of CIPN. Other therapies, although anecdotally beneficial or supported for their use in other neuropathic conditions, could not be recommended, although the guideline committee suggested that it might be reasonable to try these agents in selected patients. Available CIPN studies enrolled people who may have been exposed to different neurotoxic agents, may have received a variety of agents, and may have had comorbid conditions creating greater risk of neuropathy. This experience illustrates the complexity underlying guideline development in this nascent field of understanding painful syndromes in cancer survivors. Our committee faced these same challenges in exploring the broader context of pain and its treatment in cancer survivors.
CIPN is one of many well-recognized pain disorders, together with other treatment-related pain syndromes, such as postsurgical and postradiation pain. Hormonal therapies, such as aromatase inhibitors, can produce arthralgias. As the use of hematopoietic stem-cell transplantation expands, graft-versus-host disease (GVHD) is seen with greater frequency, leading to pain syndromes that can affect almost any organ system. In addition, immunosuppressive agents used to treat GVHD can lead to painful complications (eg, corticosteroids and avascular necrosis). Vigilance is warranted as novel treatments are being introduced that may lead to new pain syndromes. For example, muscle cramping, a debilitating painful condition that often interrupts sleep, is known to occur with polyneuropathies (including CIPN), 92 and with GVHD, 93 and has been reported as an adverse effect of newer inhibitors of the Hedgehog pathway, such as vismodegib. 94 The recent validation of a tool specific to musculoskeletal symptoms in hematopoietic stemcell transplantation will allow better characterization of this painful phenomenon. 95 The committee considered numerous pharmacologic and nonpharmacologic treatments to relieve pain, yet recommendations regarding specific interventions were difficult to make because of the limited number of studies, heterogeneity in populations and types of pain, disparity in outcomes selected, and other limitations of existing studies. Even therapies long considered foundational to the management of acute cancer pain or to relief of pain at end of life were supported by little high-quality evidence in the survivor population. Clinicians are challenged in making practice decisions in the absence of strong data.
An additional consideration when designing an analgesic regimen, particularly in the absence of strong supporting data, is the potential for harm. The ratio of benefit to harm of therapy and goals of care are different when comparing the person at the end of life with the long-term survivor. In an attempt to reduce harm, drug-drug interactions with cancer therapies or other treatments should be considered. Cytochrome P450 CYP 3A and CYP2D6 inhibitors can increase concentrations of opioids, such as codeine, oxycodone, hydrocodone, fentanyl, tramadol, and methadone, metabolized by this system. [96] [97] [98] [99] Methadone and buprenorphine can prolong the QT interval, an effect that can be potentiated by many other drugs, notably doxorubicin, nilotinib, pazopanib, sorafenib, and other chemotherapeutic agents. 100 If pain is severe and disabling, and long-term opioid therapy is being considered, the potential for opioid-related harm over time must also be evaluated. Again, the data are sparse. Persistent adverse effects such as constipation are well recognized, and evolving information about persistent endocrinopathy and risk of sleep-disordered breathing suggests that these conditions must be considered when opioid therapy is initiated and later during the course of treatment. The potential for neurotoxicities, such as persistent mental clouding, increased risk of falls in the elderly, and other phenomena may occur. Opioid-induced hyperalgesia is well described in preclinical models but has uncertain clinical importance; the potential is considered when a patient reports escalating pain in tandem with opioid dose escalation in the absence of identifiable worsening of a pain cause. A more recent line of inquiry is the effect of opioids on immune function and tumor progression, and ultimately, survival. Preclinical studies implicate m opioids in tumor progression, 101 although studies in humans are lacking. Clearly, there is an urgent need for additional research.
Opioid-related harm may also result from misuse or abuse, the development of opioid addiction, or the occurrence of drug diversion within the community. The problem of prescription drug abuse is serious, 102 leading to an increase in opioid-related deaths, but mitigation efforts designed to assess, stratify, and limit risk can enhance safety for patients, prescribers, and the community. These efforts must be coupled with the education of professionals, patients, and their family members. together with the public, about safe storage (eg, locked boxes for medications) and safe disposal (eg, take-back programs). 103 Balance in policies and regulations regarding opioids is needed to ensure appropriate access to prescription opioids for those in pain. 104 The issues described throughout this guideline are complex. The question arises regarding who should provide pain management for the cancer survivor: the oncologist and his or her team, the patient's primary care provider, a multidisciplinary pain service, or another professional? The answer may be dictated, in part, by the resources available within each community. Oncology teams providing ongoing care for cancer survivors may be the optimal group to address pain, because they routinely manage a complex regimen of cancer therapies and related symptoms. If other professionals are managing the cancer survivor's pain, clear, early, and ongoing communication should occur to delineate each team's role and responsibilities. Because knowledge deficits and inadequate training in cancer pain assessment and management have been well documented, education for all clinicians caring for these survivors is needed. Resources for education are available through ASCO and other organizations.
Patient and Clinician Communication
As therapeutic treatment options and outcomes improve, patients with cancer are living longer. Of course, this is good news, but it sometimes comes at a cost. Put simply, chronic pain from treatment-related adverse effects can significantly affect the quality of life of many cancer survivors for years after initial treatment stops. Chronic pain can develop from a variety of sources: peripheral neuropathy, muscle or bone pain, surgery, radiation, and other conditions. Comorbidity with other conditions or syndromes can make assessing chronic pain more difficult. Because post-treatment pain is so complicated, good communication between patients and their medical providers is essential. Cancer survivors are more than their cancer history or their pain; they are individuals with unique needs. They may have varying capacities to deal with a great deal of information that can sometimes be overwhelming. Just as no two cancers are alike, patients experience pain differently. Some patients may even be reluctant to discuss their pain, seeing it as a sign of weakness or fearing a recurrence; some may see it an expected and untreatable complication of their cancer treatment. That is why a pain assessment is recommended at every visit. In teasing out how they are coping, clinicians need to ask patients how chronic pain is affecting them and suggest how they can work together to better manage their symptoms and improve their quality of life. Survivors who understand all aspects of their pain treatment plan (and their role in it) may have a better overall outcome.
Health Disparities
Although ASCO clinical practice guidelines represent expert recommendations on best practices in disease management to provide the highest level of cancer care, it is important to note that many patients have limited access to health care. Lack of access because of geographic location and distance from appropriate treatment facilities is an ongoing concern for many patients. Racial and ethnic disparities in health care also contribute significantly to this problem in the United States. Patients with cancer who are members of racial/ethnic minorities suffer disproportionately from comorbidities, experience more substantial obstacles to receiving care, are more likely to be uninsured, and are at greater risk of receiving care of poor quality than are other Americans. 1, 105 Considering pain management, the literature suggests that the sources of pain disparities among racial and ethnic minorities are complex, involving patient, health care provider, and health care system factors. 106 A systematic review of pain management confirmed that racial/ethnic minorities consistently receive less adequate treatment of acute and chronic pain than do non-Hispanic whites, even after controlling for age, sex, and pain intensity.
107
Although opioid-prescribing patterns can be complex, multiple studies report that black patients are less likely to be prescribed opioids for pain than are whites.
108-110 Individuals of minority groups also seem to underreport pain intensity, contributing in part to pain-management disparities.
107 Physicians' own cultural beliefs and stereotypes regarding pain, minority individuals, and use of narcotic analgesics also play a role. 107 Awareness of these disparities in access to care should be considered in the context of this clinical practice guideline, and health care providers should strive to deliver the highest level of cancer care to these vulnerable populations.
Multiple Chronic Conditions
Creating evidence-based recommendations to inform the treatment of patients with additional chronic conditions, a situation in which the patient may have two or more such conditions, referred to as multiple chronic conditions, is challenging. Patients with multiple chronic conditions are a complex and heterogeneous population and are frequently excluded from clinical trials, making it difficult to account for all the possible permutations to develop specific recommendations for care. Insomnia and psychological distress are common conditions in patients with chronic pain, present in 17% and 90% of adult suffers, respectively. 111 The most common psychiatric disorders comorbid with chronic pain include depression, anxiety, personality disorders, and PTSD. 111, 112 Prospective studies have provided important information about the impact of comorbidity. Patients with chronic pain with these comorbidities have significantly greater functional limitations and pain intensity. 111 Moreover, evidence suggests that patients with comorbid conditions are less likely to improve with standard chronic pain treatment. 113 The optimal approach to incorporating comorbidity information in chronic pain management continues to be explored, but screening and diagnosis are key.
External Review
The draft was submitted to two external reviewers with content expertise. It was rated as high quality, and it was agreed it would be useful in practice. Specific feedback on Table 5 suggested that oncologists would find the information, as presented, overwhelming. As such, the table was revised and broken into two separate tables in an attempt to make the presentation less complicated. Other comments, such as acknowledging the paucity of evidence in the abstract and highlighting the fact that many recommendations are based on expert consensus, and the inclusion of a strong statement on the need for research in this area, were reviewed by the expert panel and integrated into the final manuscript before approval by the Clinical Practice Guideline Committee.
Guideline Implementation
ASCO guidelines are developed for implementation across health care settings. Barriers to implementation include the need to increase awareness of the guideline recommendations among front-line practitioners and survivors of cancer and their caregivers and to provide adequate services in the face of limited resources. The guideline Bottom Line Box was designed to facilitate implementation of recommendations. This guideline will be distributed widely through the ASCO Practice Guideline Implementation Network. ASCO guidelines are posted on the ASCO Web site and most often published in Journal of Clinical Oncology and Journal of Oncology Practice.
Limitation of the Research
Limitations in methodologic rigor are evident in some of the included studies. Conflict of interest is one potential source of bias. Industry-sponsored research in the area of pain medicine is a reality. As government research funding has diminished over the years, industry has stepped in, funding a greater proportion of medical research. 114 However, this funding is important for the advancement of the science. 114 Several studies included in the evidentiary base were industry funded, and their conclusions should be interpreted cautiously. Moreover, the inclusion of some observational evidence was believed to be warranted, because it allowed for long-term follow-up of patients. However, observational studies are considered to be of lower quality and, as such, the inherent limitations of such designs should be taken into consideration. In the case of evidence for risk assessment, mitigation, and universal precautions with opioid use, the inconsistency in definitions was problematic. Nonetheless, the panel reviewed the current available evidence and through consensus and clinical experience developed the recommendations.
Future Directions
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate. The identification of chronic pain syndromes in people surviving cancer is evolving as new treatments are introduced. However, numerous gaps in existing evidence have been identified and highlighted in this guideline. The expert panel believes that there is both a need and an opportunity to advance the pace and quality of clinical pain research. Comprehensive assessment, including the impact of pain on function and quality of life, is warranted for all survivors. Long-term assessment is also needed after clinical trials to better recognize novel or previously unrecognized painful consequences of treatment, including those syndromes that may occur after treatment is completed. Carefully designed, extended studies of pharmacologic and nonpharmacologic interventions to relieve pain and improve function are indicated in this population. An especially relevant and urgent need is research identifying those cancer survivors who respond optimally to opioid therapy and those at greatest risk of adverse effects. Also essential is the elucidation of opioid effects on basic systems, such as immune function and inflammatory markers, and the possible interplay with tumor growth. This will better inform patients and clinicians about the ultimate effect of opioids on survival. This call to action can set the stage for the next generation of studies to improve the evidence base of chronic pain in cancer survivors.
Additional Resources
More information, including a Data Supplement with additional evidence tables, a Methodology Supplement with information about evidence quality and strength of recommendations, slide sets, and clinical tools and resources, is available at www.asco.org/ chronic-pain-guideline and www.asco.org/guidelineswiki. Patient information is available at www.cancer.net. Visit www.asco.org/ guidelineswiki to provide comments on the guideline or to submit new evidence.
